Recent work on transgenic mice with altered innate immune systems indicates that these might be valuable models for studying the development of AMD in humans.
5 Indeed, mice lacking the chemokine Ccl2, also known as monocyte chemotactic protein-1, have been found to have many of the features of AMD by 15 months of age.
6 In the retina, Ccl2 is a chemokine that is likely released from glia, when the retina is under stress, to attract microglia/macrophages expressing the Ccr2 receptor to sites of retinal damage.
7 Loss of this chemokine has been shown to induce fundus lesions, accumulation of lipofuscin in the RPE, drusen, photoreceptor death, and choroidal neovascularization.
6 Similarly, Cx3cr1 is a receptor expressed only on microglia in the retina and it coordinates the response of the microglia to the chemokine, Cx3cl1 (fractalkine/neurotactin).
8 Cx3cl1 is commonly expressed by neurons and glia and is traditionally thought to have an anti-inflammatory or calming effect on microglia in the CNS.
8 Like Ccl2
−/−-mice, mice lacking the chemokine receptor, Cx3cr1 have been found to have white deposits in the retinal fundus and photoreceptor degeneration with age.
9 Recent work on both aged Ccl2
−/− 10 and aged Cx3cr1
−/− animals
11 indicates that the white deposits in the retinal fundus of these animals may not be the traditional drusen observed in human AMD, but instead subretinal microglia. Results from a study on aged Ccl2
−/− mice suggest that the subretinal microglia do not accelerate photoreceptor death or retinal functional loss above that seen in normal aging.
10 In contrast, subretinal microglia in the aged Cx3cr1
−/− mice have been suggested to be involved in traditional drusen formation,
11 as subretinal macrophages have been reported in histological studies of human AMD.
12